glp-1 receptor agonist antipsychotic weight gain study Efficacy and Safety of Agonists for the Management of Antipsychotic-Induced GLP-1 Agonists For Obesity In
Description
Oral semaglutide has been approved and recently marketed in Spain following evidence from the Phase 3 clinical trial program Peptide InnOvatioN for Early diabEtes tReatment (PIONEER)
17 October 2025
Reduced pricing could simplify coverage decisions and streamline patient access
The anti-inflammatory and immunological properties of SGLT-2 inhibitors
These are trademarked names not affiliated with our platform
Another oral medication, called orforglipron, is also drawing attention
